CRC

mercks-gefapixant-for-crc-treatment

Feb 06, 2023

Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?

Chronic Refractory Cough Market | Chronic refractory cough Treatment

Feb 01, 2021

Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs

Delveinsight

Aug 10, 2020

Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper